Waters Corporation (WAT)
| Market Cap | 32.62B +60.6% |
| Revenue (ttm) | 3.77B +26.4% |
| Net Income | 449.63M -31.5% |
| EPS | 6.89 -37.5% |
| Shares Out | 98.19M |
| PE Ratio | 48.24 |
| Forward PE | 22.12 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 833,635 |
| Open | 330.28 |
| Previous Close | 329.22 |
| Day's Range | 329.27 - 337.88 |
| 52-Week Range | 275.05 - 414.15 |
| Beta | 1.14 |
| Analysts | Buy |
| Price Target | 400.52 (+20.57%) |
| Earnings Date | May 5, 2026 |
About WAT
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company operates through two segments, Waters and TA. The company designs, manufactures, sells, and services liquid chromatography, as well as mass spectrometry (MS) technology systems and supports products, including chromatography columns, and other consumable products. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, p... [Read more]
Financial Performance
In 2025, Waters's revenue was $3.17 billion, an increase of 6.99% compared to the previous year's $2.96 billion. Earnings were $642.63 million, an increase of 0.75%.
Financial StatementsAnalyst Summary
According to 22 analysts, the average rating for WAT stock is "Buy." The 12-month stock price target is $400.52, which is an increase of 20.57% from the latest price.
News
Waters Corporation to Present at the Jefferies Global Healthcare Conference
MILFORD, Mass., May 18, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D.
Waters price target raised to $350 from $330 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Waters (WAT) to $350 from $330 and keeps a Hold rating on the shares.
Waters price target raised to $425 from $400 at Barclays
Barclays raised the firm’s price target on Waters (WAT) to $425 from $400 and keeps an Overweight rating on the shares. The firm updated the company’s model post the earnings…
Waters price target raised to $387 from $362 at Baird
Baird raised the firm’s price target on Waters (WAT) to $387 from $362 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results. Published…
Waters price target raised to $345 from $330 at JPMorgan
JPMorgan analyst Casey Woodring raised the firm’s price target on Waters (WAT) to $345 from $330 and keeps a Neutral rating on the shares.
Waters price target raised to $385 from $345 at TD Cowen
TD Cowen analyst Dan Brennan raised the firm’s price target on Waters (WAT) to $385 from $345 and keeps a Hold rating on the shares. The firm updated its model…
Waters price target raised to $375 from $330 at UBS
UBS raised the firm’s price target on Waters (WAT) to $375 from $330 and keeps a Neutral rating on the shares.
Waters CEO highlights China as key innovation source in the biopharma market
Waters CEO Udit Batra highlighted China as a global biopharmaceutical powerhouse. He said that innovation has fueled a rapid expansion of contract manufacturers moving into full drug development.
Waters raises annual profit forecast as biosciences unit drives growth
Lab equipment maker Waters raised its annual profit forecast on Tuesday after beating quarterly estimates, driven by robust demand for drug development tools and the strong performance of its biosci...
Early notable gainers among liquid option names on May 5th
Notable gainers among liquid option names this morning include Waters (WAT) $336.49 +34.61, Rockwell Automation (ROK) $440.40 +40.09, Intel (INTC) $105.03 +9.25, Micron (MU) $629.78 +53.33, and DuPont...
Waters Earnings Call Transcript: Q1 2026
Strong Q1 performance with double-digit organic growth, robust execution in acquired businesses, and 20% adjusted EPS growth led to raised 2026 revenue and EPS guidance. Integration and synergy realization are ahead of plan, with new product launches and China localization supporting future growth.
Waters raises FY26 EPS view to $14.40-$14.60 from $14.30-$14.50
Consensus $14.38. Sees FY26 revenue $6.41B-$6.46B, consensus $6.42B. Batra continued: “As we look ahead, we are raising our guidance to reflect the increased momentum we are seeing across our business...
Waters reports Q1 adjusted EPS $2.70, consensus $2.31
Reports Q1 revenue $1.27B, consensus $1.2B. “Thanks to the hard work of our teams, we delivered an excellent first quarter as a combined company,” said Udit Batra, President & Chief…
Waters sees Q2 adjusted EPS $2.95-$3.05, consensus $3.00
Sees Q2 revenue $1.62B-$1.63B, consensus $1.62B.
Waters Corporation (NYSE: WAT) Reports First Quarter 2026 Financial Results
First Quarter 2026 Highlights Total reported revenue of $1.267 billion exceeded the high end of the guidance range by $56 million, driven by strong outperformance in both organic revenue and the acqui...
Waters Corporation Schedules First Quarter 2026 Earnings Conference Call
MILFORD, Mass., April 20, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q1 2026 financial results conference call on Tuesday, May 5, 2026 at 8:30 a.m.
Waters Debuts Industry-First Extended-Range MALS Detector for UHPLC/UPLC, Powering Rapid Characterization of Large Molecules
Delivers up to 4x faster chromatographic run times to accelerate decisions across discovery, development, and quality workflows.1,3 Achieves 10x improvement in absolute molar mass and extended sizing,...
Waters price target lowered to $330 from $370 at UBS
UBS analyst Lu Li lowered the firm’s price target on Waters (WAT) to $330 from $370 and keeps a Neutral rating on the shares. The firm updated the company’s model.
Waters announces FDA clearance of Onclarity HPV Self-Collection Kit
Waters (WAT) announced that the U.S. FDA has cleared the Onclarity HPV Self-Collection Kit and approved the BD Onclarity HPV Assay with extended genotyping for at-home use, marking a significant…
Waters Announces FDA Clearance of the Most Comprehensive At-Home Cervical Cancer Screening Tool, the Onclarity HPV Self-Collection Kit and FDA-Approved HPV Assay
FDA-approved BD Onclarity™ HPV Assay is the most comprehensive screening tool for HPV in the U.S.1,4 with extended genotyping and end-to-end automated lab workflows. At-home self-collection reduces si...
Waters upgraded to Outperform from In Line at Evercore ISI
Evercore ISI analyst Vijay Kumar upgraded Waters (WAT) to Outperform from In Line with a $350 price target The firm believes Q1 numbers are “achievable” and a second half ramp…
Waters reinstated with a Buy at Goldman Sachs
Goldman Sachs reinstated coverage of Waters (WAT) with a Buy rating and $375 price target representing 26% upside. The firm says the majority of the headwinds that impacted the company’s…
Waters price target lowered to $330 from $370 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Waters (WAT) to $330 from $370 and keeps a Hold rating on the shares. The firm says shares upside is contingent on…
Waters director buys $144.7K in common stock
In a regulatory filing, Waters (WAT) disclosed that its director Wei Jiang bought 500 shares of common stock on March 16th in a total transaction size of $144.7K. Shares are…
Waters Prices Offering of Senior Notes
MILFORD, Mass., March 18, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) (the "Company" or "Waters") today announced that it has priced an offering (the "Offering") of $3.5 billion aggregate prin...